Edition:
United Kingdom

People: Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

13.62USD
18 Sep 2019
Change (% chg)

-- (--)
Prev Close
$13.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
226,794
52-wk High
$19.48
52-wk Low
$9.14

Wilson, James 

Mr. James N. Wilson is an Independent Chairman of the Board of Corcept Therapeutics Incorporated. He has served as a director and as Chairman of our Board since 1999. From 2005 to 2018, he was also a member of the Board of NuGEN Technologies, Inc. (“NuGEN”), a provider of systems for genomic analysis. From 2002 to 2009, Mr. Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc. (“Amylin”), a publicly-traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the Board of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr. Wilson was Chief Operating Officer of Syntex Corporation (“Syntex”), which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation (“Neurex”), which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona. Mr. Wilson brings to our Board extensive experience in the biotechnology industry, as both a senior executive and director.

Basic Compensation

Total Annual Compensation, USD 120,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 638,669
Fiscal Year Total, USD 758,669

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Wilson

758,669

Joseph Belanoff

6,314,620

Gary Robb

2,845,670

Sean Maduck

2,806,070

Andreas Grauer

--

George Baker

267,889
As Of  31 Dec 2018